Estudos preliminares através de microarray nos mostraram que a E3 ligase Mdm2 foi regulado positivamente no músculo de animais hipertireoideos. Dessa forma, nós inferimos uma possível relação de Mdm2 com a atrofia causada por T3. Para testar nossa hipótese, ratos foram induzidos ao hipertireoidismo para análises subsequentes. Concomitante com a perda de massa muscular foi confirmado um aumento da expressão de Mdm2 tanto no nível gênico (p<0.05) quanto protéico. Interessantemente, Mdm2 foi preferencialmente expresso em fibras tipo I, mostrando maior sensibilidade dessas fibras ao T3. Além disso, foi observado uma diminuição severa na expressão de Pax7/MyoD associado à superexpressão de Mdm2, sugerindo inatividade das células satélites. Surpreendentemente, a inibição de Mdm2 em miotubos cultivados provocou uma diminuição severa no diâmetro destes (~35%, p<0.05), ou seja, tal inibição foi incapaz de minimizar a proteólise muscular causada por T3. Portanto, nós concluímos que a responsividade de Mdm2 ao T3 agiria como um mecanismo compensatório numa tentativa de minimizar a proteólise muscular causada pelo hipertireoidismo. Esta conclusão é reforçada pela atrofia observada em miotubos durante a inibição de Mdm2 sem a presença de T3. / Previous studies in our lab through microarray assay observed Mdm2, an E3 ligase, up regulated in soleus muscle from hyperthyroid rats. In this sense, we inferred that Mdm2 could be related to muscle atrophy caused by T3. To test our hypothesis, rats were induced to experimental hyperthyroidism for subsequent analysis. Along the muscle mass loss, the increase on Mdm2 gene expression was confirmed (p<0.05) as well as protein expression by RT-PCR and Western Blot, respectively. Interestingly, Mdm2 was expressed predominantly in fiber I type during T3 treatment, demonstrating a higher sensibility when compared to type II fiber. Moreover, it was observed a severe decrease in Pax7/MyoD labeling, associated to an increase on Mdm2 labeling, suggesting that T3 could be associated with inactivation of satellite cells. Surprisingly, Mdm2 inhibition in myotubes have induced severe decrease on myotubes diameter (~35%, p<0.05), in other words, Mdm2 inhibition was not able to decrease muscle proteolysis during high levels of T3. Thus, the increase on Mdm2 levels could be a compensatory effect to reduce the muscle mass loss during T3 treatment. This conclusion is highlighted by the myotubes atrophy observed during the Mdm2 inhibition without T3 treatment.

Une des caractéristiques des cellules tumorales est leur habileté à échapper à la mort cellulaire. Pour y parvenir, elles ont développé une stratégie consistant à éliminer sélectivement les mitochondries endommagées par un processus de mitophagie. L’acteur principal de la mitophagie est l’ubiquitine ligase Parkin ; mais elle est mutée ou absente dans la majorité des cancers. Nous avons découvert qu’une autre ligase, ARIH1, appartenant à la même famille des RBR ligases que Parkin, est capable d’induire la mitophagie en réponse à un stress. Contrairement à Parkin, ARIH1 est surexprimée dans de nombreux cancers, notamment dans les cancers du poumon permettant ainsi une augmentation de la mitophagie conférant ainsi à ces cellules une résistance au stress induit par des agents chimiothérapeutiques. La mort cellulaire la mieux caractérisée est l’apoptose qui est directement liée à l’activation de caspases. Il a pourtant été établi qu’une inhibition des caspases ne permet pas d’empêcher la mort cellulaire car il existe la « mort cellulaire indépendante des caspases » ou CICD. Cependant, sa définition moléculaire précise reste toujours inconnue. Ainsi dans ce but, un criblage siRNA pan génomique a révélé l’importance de la voie ubiquitine/protéasome. Nous avons pu identifier en particulier une enzyme E3 ligase comme étant protectrice de la CICD. Cette enzyme est surexprimée dans de nombreux cancers et pourrait permettre aux cellules cancéreuses de résister à la CICD et favoriser la progression tumorale. En résumé, ce travail a permis de souligner l’importance des ubiquitines ligases dans les mécanismes d’échappement à la mort cellulaire mis en place par les cellules cancéreuses. / One of the hallmarks of tumor cells is their ability to escape cell death.To achieve this, they have developed a strategy of selectively removing damaged mitochondria by a process of mitophagy. The main actor of mitophagy is the ubiquitin ligase Parkin; but it is mutated or absent in the majority of cancers. We have discovered that another ligase, ARIH1, belonging to the same family of RBR ligases as Parkin, is capable of inducing mitophagy in response to stress. In contrast to Parkin, ARIH1 is overexpressed in many cancers, especially in lung cancer, allowing an increase in mitophagy conferring resistance to stress induced by chemotherapeutic agents. The most characterized cell death pathway is apoptosis, which is directly related to caspases activation. However, it has been established, that caspase inhibition does not prevent cell death because there is another type of cell death called "caspase-independent cell death" or CICD. However, its precise molecular definition is still unknown. Thus for this purpose, pan-genomic siRNA screening was performed and revealed the importance of the ubiquitin / proteasome pathway. In particular, we have been able to identify an enzyme E3 ligase as being protective towards CICD. This enzyme is overexpressed in many cancers and could allow cancer cells to resist CICD and promote tumor progression. In summary, this work has highlighted the importance of ubiquitin ligases in the escape mechanisms to cell death implemented by cancer cells.

MDM2, murine double minute 2, is a RING type-E3 ligase protein and also an oncogene. MDM2 plays a critical role in determining the steady levels and activity of p53 in cells using two mechanisms. The N-terminal domain of MDM2 binds to the transactivation domain of p53 and inhibits its transcriptional activity. The RING domain of MDM2 plays a role in the ubiquitination (and degradation) of p53. Several proteins are responsible for the ubiquitination mechanism including the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). Since the E2-E3 interaction is essential for ubiquitination, the protein-protein recognition site is a potential drug target. Two different MDM2 RING constructs were expressed and purified: MDM2RING (residues 386-491) and MDM2RING△C (residues 386-478). Both constructs were characterised using dynamic light scattering, size exclusion chromatography, mass spectrometry, NMR and electron microscopy. E3 ligase activity in vitro was also studied. Taken together these results showed that the MDM2RING construct formed a concentration-dependent oligomeric structure. In contrast, the MDM2RING△C construct formed a dimer at all concentrations. Both MDM2RING and MDM2RING △ C retain E3 ligase activity. However, the MDM2RING△C construct is less active. Full length E2 enzyme UbcH5a was also purified. Various biophysical techniques were used to study its interaction with MDM2 as well as with potential small molecule inhibitors as in principle, small molecules which disrupt the interaction between MDM2 and UbcH5a, could prevent/promote ubiquitination of p53. The dimerisation of MDM2 is important for its E3 activity and the C8-binding site potentially provides a second druggable site. In this work, peptide 9, which has the same sequence as the C-terminus of MDMX (an MDM2 homologue) was found to inhibit MDM2 E3 activity. Various biological techniques including NMR, fluorescence anisotropy, and electrospray mass spectrometry were used to investigate the interaction between two inhibitory peptides and MDM2. A major part of project involved virtual screening (VS) to search for small molecules which can affect MDM2-dependent ubiquitination. Three potential targets were considered: (1) the C8-binding site of MDM2; (2) the UbcH5a-binding site of MDM2; and (3) the MDM2-binding site of UbcH5a. Several small molecules were identified using our virtual screening database-mining and docking programs that were shown to affect MDM2-dependent ubiquitination of p53. In terms of understanding the complex biochemical mechanism of MDM2 this work provides two interesting and functionally relevant observations: (i) the MDM2 RING△C construct is a dimer as this would not be expected form the existing studies, and has less E3 ligase activity than MDM2RING; (ii) small molecules that bind MDM2 on the E2 binding site enhanced E3 ligase activity. One model to explain these observations is that binding of small molecule activators family to the RING induces a change in the conformation of the Cterminal tail residues which may enhance E2 binding.

<p>The Anaphase Promoting Complex/Cyclosome (APC/C) is a RING E3 ligase that plays essential roles both within and outside of the cell cycle. At the onset of anaphase, the APC/C targets cyclin B and securin for degradation, initiating chromosome separation and mitotic exit. Regulation of APC/C activity is critical for a functional cell cycle, and this is largely mediated by cytostatic factor (CSF) activity and the Spindle Assembly Checkpoint (SAC). </p> <p>Prior to fertilization, vertebrate eggs are arrested in metaphase of meiosis II by CSF activity, a key component of which is the APC/C inhibitor Emi2. Although the roles and regulation of Emi2 in maintaining CSF arrest have been extensively studied, its function during the oocyte maturation process, especially at the meiosis I to meiosis II (MI-MII) transition, was not well understood. Studies presented in this dissertation characterize an Emi2-mediated auto-inhibitory loop of the APC/C that provides the molecular basis of a critical biochemical event during the MI-MII transition--the partial degradation of cyclin B. In brief, phosphorylation of the Emi2 N-terminus by Cdc2/cyclin B targets it for proteasomal degradation in meiosis I (MI). During anaphase of MI, the APC/C triggers its own inactivation by degrading cyclin B, therefore stabilizing its inhibitor, Emi2. The timely inactivation of APC/C activity prevents the complete inactivation of Cdc2 kinase, which is crucial for prohibiting S phase onset and parthenogenetic activation of the oocytes.</p> <p>To better understand the regulation of the APC/C, a number of the studies presented here are aimed at identifying the mechanism for Emi2 inhibition of the APC/C. Many APC/C inhibitors have been reported to function as "pseudosubstrates", which inhibit the APC/C by preventing substrate binding. After carefully examining the ubiquitin reactions mediated by the APC/C in vitro, we have found that it is the last step in the ubiquitylation process, where ubiquitin is transferred from a charged E2 to the substrate, that is targeted by Emi2. In addition, biochemical studies have also revealed that Emi2 itself has RING-dependent ligase activity and this activity enables it to inhibit the APC/C in a sub-stoichiometrical manner. </p> <p>Although the ultimate goal for both CSF activity and the SAC signaling pathway is APC/C inhibition, a much more complicated regulatory network is known to control SAC. Previous researches in our lab have identified Xnf7 to be an APC/C inhibitor that is required for the SAC pathway in Xenopus egg extract. In an effort to characterize the human Xnf7 homolog, we have found that Trim39, a protein that has been implicated in apoptosis regulation, is required for the SAC pathway in RPE cells. Like Emi2, both Xnf7 and Trim39 are RING E3 ligases whose activity is essential for their function. Interestingly, the ligase activity of both proteins appears to be regulated by the checkpoint. While we continue to characterize the roles and regulation of both Trim39 and Xnf7 in the SAC, future investigations into the mechanisms that underlie APC/C inhibition by all the three E3 ligases--Emi2, Xnf7 and Trim39--would be of great interest.</p> / Dissertation

The covalent modification of proteins with a suite of molecular tags, a process termed post-translational modification, is a powerful means to enhance the proteomic complexity of an organism far beyond that which is directly encoded by its genome. A particularly widespread form of modification involves the conjugation of the protein ubiquitin to specified substrates, which serves to regulate numerous cellular processes. The mechanism of ubiquitin conjugation, known as ubiquitylation, requires E3 ubiquitin ligases that specify and recruit substrate proteins for ubiquitin conjugation. Recent insights into the mechanisms of ubiquitylation demonstrate that E3 ligases can possess active regulatory properties beyond those of a simple assembly scaffold. This thesis describes the dimeric structure of the E3 ligase adaptor protein SPOP in complex with the N-terminal domain of Cul3 at 2.4 Å resolution. Here, it is demonstrated that SPOP forms large oligomers that can form heteromeric species with the closely related paralog SPOPL. In combination, SPOP and SPOPL form a molecular rheostat that can fine-tune E3 ubiquitin ligase activity by affecting the oligomeric state of the E3 complex. These results reveal a mechanism through which adaptor protein self-assembly may provide a graded level of regulation of the SPOP/Cul3 E3 ligase toward its multiple protein substrates.

The covalent modification of proteins with a suite of molecular tags, a process termed post-translational modification, is a powerful means to enhance the proteomic complexity of an organism far beyond that which is directly encoded by its genome. A particularly widespread form of modification involves the conjugation of the protein ubiquitin to specified substrates, which serves to regulate numerous cellular processes. The mechanism of ubiquitin conjugation, known as ubiquitylation, requires E3 ubiquitin ligases that specify and recruit substrate proteins for ubiquitin conjugation. Recent insights into the mechanisms of ubiquitylation demonstrate that E3 ligases can possess active regulatory properties beyond those of a simple assembly scaffold. This thesis describes the dimeric structure of the E3 ligase adaptor protein SPOP in complex with the N-terminal domain of Cul3 at 2.4 Å resolution. Here, it is demonstrated that SPOP forms large oligomers that can form heteromeric species with the closely related paralog SPOPL. In combination, SPOP and SPOPL form a molecular rheostat that can fine-tune E3 ubiquitin ligase activity by affecting the oligomeric state of the E3 complex. These results reveal a mechanism through which adaptor protein self-assembly may provide a graded level of regulation of the SPOP/Cul3 E3 ligase toward its multiple protein substrates.

The MDM2 protein regulates the tumour suppressor protein p53, acting as its chaperone, regulating its translation and targeting p53 for degradation by the 26s proteasome via its E3 ligase activity. The E3 ligase activity of MDM2 is dependent on its C-terminal RING domain. E3 ligases containing a RING domain are traditionally thought to catalyse the transfer of ubiquitin from their conjugating enzyme (E2) partner to the target protein, in the final step of the ubiquitination cascade. Various E2 enzymes have been shown to interact with their partner E3 ligases, yet evidence for the interaction between MDM2 and its partner E2, UbcH5α has not yet been shown. It has been reported that the reason for this lack of evidence is that the interaction between the two is highly unstable. Here I show that MDM2 forms a stable isolatable interaction with UbcH5α, the C-terminal tail of MDM2 is not necessary for this interaction. Although RING E3 ligases were not previously thought to interact with ubiquitin, preliminary evidence is emerging that suggests that this interaction is possible indeed I show that MDM2 and ubiquitin form a stable complex. I demonstrate that UbcH5α and ubiquitin both interact with the RING of MDM2, specifically the 20 most C-terminal amino acids of MDM2. My results show that both these proteins can bind this region of the RING simultaneously. I also highlight specific residues including tyrosine 489 and arginine 479 important for UbcH5α and ubiquitin binding respectively and the negative affect that these mutations have on the E3 ligase activity of MDM2 towards p53. Furthermore I show by limited proteolysis and hydrogen deuterium exchange that UbcH5α can be allosterically activated by MDM2. A novel peptide phage display technique linked to next generation sequencing was developed to further confirm an allosteric change and demonstrates that UbcH5α has different binding specificity for peptides when in a free or ligand bound conformation. MDM2 is a popular target for cancer therapeutics due to its dysregulation throughout many cancer types, including 30% of soft tissue sarcomas. Dissecting the mechanism of MDM2 function is an important step in identifying specific drugable interfaces on MDM2 and its interacting partners so that effective therapeutics can be designed.

No description available.

SUMMARY PtaRHE1 is a poplar (Populus tremula x P. alba) gene encoding a REALLY INTERESTING NEW GENE (RING) domain-containing protein. RING proteins are largely represented in plants and play important roles in the regulation of many developmental processes as well as in plant-environment interactions. In this thesis, we present a functional characterization of PtaRHE1. To gain further insight into the role of this gene, molecular and genetic alteration approaches were used. The results of in vitro ubiquitination assays indicate that PtaRHE1 protein is a functional E3 ligase and this activity was shown to be specific with the human UbCH5a, among the tested ubiquitin-conjugating enzymes. Histochemical GUS stainings showed that the PtaRHE1 promoter is induced by plant pathogens and by elicitors such as salicylic acid and cellulase and is also developmentally regulated. In silico predictions and the transient expression of PtaRHE1-GFP fusion protein in N. tabacum epidermal cells revealed that PtaRHE1 is localized both in the plasma membrane and in the nucleus. The localization of expression of PtaRHE1 in poplar stem by in situ hybridization indicated that PtaRHE1 transcripts are localized within the cambial zone mainly in ray cells, suggesting a role of this gene in vascular tissue development and/or functioning. The overexpression of PtaRHE1 in tobacco resulted in a pleiotropic phenotype characterized by a curling of leaves, the formation of necrotic lesions on leaf blades, growth retardation as well as a delay in flower transition. Plant genes expression responses to PtaRHE1 overexpression provided evidence for the up-regulation of defence and/or programmed cell death (PCD) related genes. Moreover, genes coding for WRKY transcription factors as well as for MAPK, such as WIPK, were also found to be induced in the transgenic lines as compared to the wild type (WT). Taken together, our results suggest that the E3 ligase PtaRHE1 plays a role in the signal transduction pathways leading to defence responses against biotic and abiotic stresses. Identification of PtaRHE1 target(s) is required in order to fully assess the role of this E3 ligase in the ubiquitination-mediated regulation of defence response./ RÉSUMÉ PtaRHE1 est un gène qui code pour une protéine possédant un domaine RING (REALLY INTERESTING NEW GENE) chez le peuplier (Populus tremula x P. alba). Les protéines de type RING sont très répandues chez les végétaux où elles jouent de rôles importants dans la régulation de plusieurs processus de développement et également dans les interactions plantes-environnement. Dans le cadre de ce travail, nous avons procédé à la caractérisation fonctionnelle du gène PtaRHE1. Dans le but de découvrir la fonction de ce gène, nous avons adopté une stratégie faisant usage d’approches moléculaires ainsi que de l’altération de l’expression génique. Les résultats obtenus montrent que la protéine PtaRHE1 est une E3 ligase et que cette activité enzymatique est spécifique à l’Ubiquitin-Conjugating enzym humaine UbCH5a. Les résultats du test histochimique GUS ont montré que le promoteur du gène PtaRHE1 est induit par des pathogènes et aussi par l’acide salicylique et la cellulase. Par ailleurs, ce promoteur est aussi régulé au cours du développement végétal. Les prédictions in silico et l’expression transitoire d’une fusion traductionnelle GFP-PtaRHE1, au niveau de l’épiderme des feuilles du tabac N. tabacum, ont révélé que la protéine PtaRHE1 se situe tant au niveau de la membrane cytoplasmique qu’au niveau du noyau. La localisation de l’expression du gène PtaRHE1, par les techniques d’hybridation in situ, montre que les transcrits de ce gène se retrouvent principalement au niveau des cellules de rayon, dans la zone cambiale, suggérant que ce gène pourrait jouer un rôle dans le développement ou la formation du tissu vasculaire. La surexpression du gène PtaRHE1 chez le tabac a conduit à l’obtention d’un phénotype pléiotropique caractérisé par un recroquevillement (incurvation) des feuilles, la formation des lésions nécrotiques sur le limbe, un retard de croissance ainsi qu’un retard dans la transition florale. L’analyse de la réponse de l’expression de différents gènes à la surexpression de PtaRHE1 a mis en évidence l’induction des gènes liés à la défense et ou à la mort cellulaire programmée. En outre, l’expression des gènes codant pour des facteurs de transcription WRKY et aussi des MAPKs, tel que WIPK, était aussi plus élevée chez les plantes transgéniques comparées au type sauvage. Les résultats de ce travail suggèrent que PtaRHE1, comme E3 ligase, pourrait jouer un rôle dans la transduction des signaux cellulaires conduisant aux réactions de défense contre les stress biotiques et abiotiques. L’identification de la (des) cible(s) de PtaRHE1 est indispensable pour la compréhension du rôle de cette protéine dans la régulation des réponses de défense par l’intermédiaire de l’ubiquitination.

Seed maturation is an important process that is evolutionarily advantageous, allowing for seed dispersal and germination under favourable growth conditions. The B3-domain transcription factor FUSCA3 (FUS3) is a master regulator of seed maturation and controls developmental phase transitions through hormonal regulation in Arabidopsis thaliana. The aim of this study was to determine the post-translational regulation of FUS3 during embryonic and vegetative development. Here, FUS3 was found to interact with the E3 ubiquitin ligase ABI3-INTERACTING PROTEIN2 (AIP2) in yeast two-hybrid, in vitro, and in planta assays. Analysis of transcriptional and translational reporters also showed overlapping spatial and temporal expression patterns of AIP2 and FUS3. Furthermore, in vitro FUS3 degradation was delayed in aip2-1 mutant and increased FUS3-GFP levels were observed during mid-embryogenesis in aip2-1. Finally, double transgenic plants overexpressing AIP2 and FUS3 showed reduced FUS3 levels and reversion of the gain-of-function FUS3 phenotypes back to WT. Together, these results indicate that AIP2 is a negative regulator of FUS3.